Methods for any additional analyses {20b}
hallucinations
The exploratory end point, drug use, will be analyzed by comparing total number of oxycodone tablets used between oxycodone and oxycodone/cannabis and total number of cannabis inhalations between the cannabis and oxycodone/cannabis groups. These later comparisons are considered exploratory and no alpha-value will be a priori set for level of significance. All other outcome variables will not be compared but presented as either mean ± SD, median (interquartile range), number, or percentage, as deemed appropriate. Additionally, we will analyze the different components of the composite AU score. For example, we will separate opioid from cannabis side effects (e.g., hallucinations, paranoia) and analyze these separately.